Bockmeyer M, Riebenfeld D, Clasen B
ENT Department, Würzburg, Germany.
Clin Ther. 1994 Jul-Aug;16(4):653-61.
Brodimoprim, a new dehydrofolate reductase inhibitor, was compared with cephalexin in the treatment of patients with acute sinusitis. A total of 49 patients were randomly assigned to receive either brodimoprim 200-mg tablets once a day (400 mg on the first day as a loading dose) or cephalexin 500-mg tablets three times a day for 8 to 12 days. Nearly all patients treated were judged clinically cured/improved; in fact, only one failure (in the cephalexin group) was noted. In the 45 assessable patients, the time until disappearance of the symptoms and the duration of treatment did not differ significantly between the two groups. A bacteriologic examination was performed in all patients at baseline as well as at the end of therapy. Bacteriologic eradication was obtained in 88% of the patients treated with brodimoprim and in 76% of those receiving cephalexin. Both compounds were generally well tolerated (one patient in the brodimoprim group complained of skin reactions). These results suggest that once-daily treatment with brodimoprim represents safe and effective therapy for adults with acute bacterial sinusitis.
新的脱氢叶酸还原酶抑制剂溴莫普明与头孢氨苄治疗急性鼻窦炎患者的疗效比较。49例患者随机分组，分别接受每日1次口服溴莫普明200mg片剂（首日负荷剂量400mg）或每日3次口服头孢氨苄500mg片剂，疗程8至12天。几乎所有接受治疗的患者临床判断均治愈/好转；实际上，仅1例治疗失败（头孢氨苄组）。在45例可评估患者中，两组症状消失时间和疗程无显著差异。所有患者在基线期及治疗结束时均进行了细菌学检查。接受溴莫普明治疗的患者细菌清除率为88%，接受头孢氨苄治疗的患者为76%。两种药物总体耐受性良好（溴莫普明组1例患者诉有皮肤反应）。这些结果表明，对于成人急性细菌性鼻窦炎，每日1次服用溴莫普明是安全有效的治疗方法。
